Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 May;16(3):401-409.
doi: 10.1016/j.jcf.2017.01.006. Epub 2017 Feb 24.

The cumulative effects of intravenous antibiotic treatments on hearing in patients with cystic fibrosis

Angela C Garinis  1 , Campbell P Cross  2 , Priya Srikanth  3 , Kelly Carroll  4 , M Patrick Feeney  5 , Douglas H Keefe  6 , Lisa L Hunter  7 , Daniel B Putterman  5 , David M Cohen  8 , Jeffrey A Gold  9 , Peter S Steyger  4
Affiliations

The cumulative effects of intravenous antibiotic treatments on hearing in patients with cystic fibrosis

Angela C Garinis et al. J Cyst Fibros. 2017 May.

Abstract

Background: Aminoglycosides (AGs) and glycopeptides are antibiotics essential for treating life-threatening respiratory infections in patients with cystic fibrosis (CF). The goal of this study was to examine the effects of cumulative intravenous (IV)-AG (amikacin and/or tobramycin) and/or glycopeptide (vancomycin) dosing on hearing status in patients with CF.

Methods: Hearing thresholds were measured from 0.25 to 16.0kHz, in 81 participants with CF. Participants were categorized into two groups: normal hearing in both ears (≤25dB HL for all frequency bands) or hearing loss (>25dB HL for any frequency band in either ear). Participants were also characterized into quartiles by their cumulative IV-AG (with or without vancomycin) exposure. Dosing was calculated using two strategies: (i) total number of lifetime doses, and (ii) total number of lifetime doses while accounting for the total doses per day. This was referred to as the "weighted" method.

Results: Participants in the hearing loss group were significantly older than those in the normal-hearing group. After adjusting for gender and age at the time of hearing test, participants in the two highest-quartile exposure groups were almost 5 X more likely to have permanent sensorineural hearing loss than those in the two lowest-quartile exposure groups. There was a small group of CF patients who had normal hearing despite high exposure to IV-antibiotics.

Conclusions: Cumulative IV-antibiotic dosing has a significant negative effect on hearing sensitivity in patients with CF, when controlling for age and gender effects. A trend for increasing odds of hearing loss was associated with increasing cumulative IV-antibiotic dosing.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Audiometric profiles ears in the lowest dosing group (Q1) up to the highest dosing group (Q4). Age (median and range) is also displayed for individual ears within each dosing quartile. Individual hearing thresholds across the conventional (0.25 to 8.0 kHz) and extended high frequency (9.0 to 16.0 kHz) ranges for participants in the lowest dosing group (Q1) up to the highest dosing group (Q4). The ear with the greatest degree of hearing loss for each participant is displayed. Participants who were older than the median age for each quartile are displayed in colored lines.
Figure 2
Figure 2. Odds ratios for association of cumulative IV dose for AG (± vancomycin) exposure
(Q1 = Referent; horizontal line at 1) Odds ratios for association of cumulative IV antibiotic dosing. There was a significant trend of increased odds of SNHL with increased dosing quartiles (p for trend = 0.01) when Q1 was used as the referent group.
See this image and copyright information in PMC

References

    1. Martins LM, Camargos PA, Becker HM, Becker CG, Guimaraes RE. Hearing loss in cystic fibrosis. Int J Pediatr Otorhinolaryngol. 2010;74(5):469–73. - PubMed
    1. Mulheran M, Degg C, Burr S, Morgan DW, Stableforth DE. Occurrence and risk of cochleotoxicity in cystic fibrosis patients receiving repeated high-dose aminoglycoside therapy. Antimicrob Agents Chemother. 2001;45(9):2502–9. - PMC - PubMed
    1. Cheng AG, Johnston PR, Luz J, Uluer A, Fligor B, Licameli GR, et al. Sensorineural hearing loss in patients with cystic fibrosis. Otolaryngol Head Neck Surg. 2009;141(1):86–90. - PubMed
    1. Prayle A, Smyth AR. Aminoglycoside use in cystic fibrosis: therapeutic strategies and toxicity. Curr Opin Pulm Med. 2010;16(6):604. - PubMed
    1. Moore RDSC, Lietman PS. Risk factors for the development of auditory toxicity in patients receiving aminoglycosides. J Infect Dis. 1984;149:23–30. - PubMed

MeSH terms